Get the Stockscreener App
13.44
0.00%
0.00
Pre-market:
13.46
0.02
+0.15%
Organon Co stock is traded at $13.44, with a volume of 2.12M.
It is up +0.00% in the last 24 hours and up +0.30% over the past month.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
See More
Previous Close:
$13.44
Open:
$13.43
24h Volume:
2.12M
Relative Volume:
0.25
Market Cap:
$3.53B
Revenue:
$6.16B
Net Income/Loss:
$246.00M
P/E Ratio:
14.32
EPS:
0.9387
Net Cash Flow:
$708.00M
1W Performance:
+0.37%
1M Performance:
+0.30%
6M Performance:
+91.45%
1Y Performance:
+33.86%
1-Day Range:
$13.42
$13.46
1-Week Range:
$13.37
$13.49
52-Week Range:
$5.69
$13.49
Organon Co Stock (OGN) Company Profile
Name
Organon Co
Sector
Industry
Phone
551-430-6000
Address
30 HUDSON STREET, JERSEY CITY
Compare OGN vs LLY, JNJ, ABBV, NVS, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
13.44 | 3.53B | 6.16B | 246.00M | 708.00M | 0.9387 |
LLY
Lilly Eli Co
|
1,129.35 | 1.01T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
235.66 | 567.28B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
221.59 | 391.50B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
151.56 | 289.19B | 54.66B | 13.58B | 16.05B | 7.0171 |
MRK
Merck Co Inc
|
114.90 | 283.78B | 65.51B | 8.93B | 14.12B | 3.5532 |
Organon Co Stock (OGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Underweight |
| Oct-27-25 | Downgrade | Piper Sandler | Overweight → Underweight |
| May-02-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-06-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-03-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-21-23 | Initiated | Barclays | Overweight |
| Mar-16-23 | Initiated | Raymond James | Outperform |
| Oct-14-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-06-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-07-21 | Initiated | Piper Sandler | Neutral |
| Sep-01-21 | Initiated | BofA Securities | Buy |
| Jul-22-21 | Initiated | Citigroup | Buy |
| Jun-15-21 | Initiated | JP Morgan | Neutral |
| Jun-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-10-21 | Initiated | Evercore ISI | Outperform |
View All
Organon Co Stock (OGN) Latest News
Is TOFIDENCE’s Expanded CRS and COVID Label Altering The Investment Case For Organon (OGN)? - Yahoo Finance
Organon (OGN) director Shalini Sharp receives 17,857 phantom stock units as cash-settled award - Stock Titan
Organon (OGN) director Ramona Sequeira receives 17,857 phantom stock units as cash-settled award - Stock Titan
Organon (OGN) director receives 17.8K phantom stock units as compensation - Stock Titan
Organon (OGN) director granted cash-settled phantom stock tied to shares - Stock Titan
Organon (OGN) director awarded 17,857 phantom stock units as cash-settled compensation - Stock Titan
Organon (OGN) director receives phantom stock award, lifting holdings above 81,000 units - Stock Titan
Organon (OGN) director awarded 17,857 phantom stock units under savings plan - Stock Titan
Organon (OGN) director Alan Ezekowitz awarded 17,857 phantom stock units - Stock Titan
Organon (OGN) director awarded phantom stock units tied to shares - Stock Titan
Organon wins FDA nod to expand TOFIDENCE use in severe CRS & COVID-19 - MSN
Sun Pharma to acquire US-based Organon in nearly $11.75 billion deal - DD News
Press Release: Organon Reports Results for the First Quarter Ended March 31, 2026 - Moomoo
OGNOrganon & Co Stock Price and Quote - Finviz
Sun Pharma to buy Organon for $11.75B in record overseas deal - MSN
Organon & Co. Announces Results of 2026 Annual Meeting and Approves Incentive Stock Plan in Form 8-K Filing - Minichart
Organon Wins FDA Nod to Expand TOFIDENCE Use in Severe CRS & COVID-19 - Zacks Investment Research
Sector Gamma AS Has $2.15 Million Stock Position in Organon & Co. $OGN - MarketBeat
Private Management Group Inc. Acquires 1,204,979 Shares of Organon & Co. $OGN - MarketBeat
Organon & Co stock hits 52-week high at 13.48 USD - Investing.com Nigeria
Organon (NYSE: OGN) holders back amended 2021 incentive plan adding 8M shares - Stock Titan
Organon & Co. (NYSE:OGN) Sets New 1-Year HighStill a Buy? - MarketBeat
Brandes Investment Partners LP Has $4.35 Million Stock Holdings in Organon & Co. $OGN - MarketBeat
Organon & Co. (OGN) 10K Form and Latest SEC Filings 2026 - MarketBeat
Organon wins US approval to widen use of arthritis biosimilar drug - ETPharma.com
OGN News | ORGANON & CO (NYSE:OGN) - ChartMill
Sun Pharma seals $11.8 bn Organon deal, eyes global top 25 spot - MSN
SBI Set to Join Global Lenders Backing Sun Pharma's USD 12 Billion Organon Acquisition - Medical Dialogues
FDA expands Organon’s tocilizumab biosimilar indications - Investing.com UK
Organon & Co. (NYSE:OGN) Given Consensus Rating of "Reduce" by Brokerages - MarketBeat
Organon Expands Tofidence Label With FDA Approval for Additional Indications - marketscreener.com
FDA expands Organon’s tocilizumab biosimilar indications By Investing.com - Investing.com Australia
Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE - Business Wire
Halper Sadeh LLC is Investigating Whether NUVL, SUNE, OGN, TMHC are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
SBI Set to Join Global Lenders in Funding Sun Pharma’s $12 Bn Organon Acquisition - outlookbusiness.com
SBI May Commit $1 Billion to Support Sun Pharma’s $12 Billion Organon Acquisition - India Infoline
SBI in $1 billion funding for Sun Pharma’s US deal - The Economic Times
What Sparked Organon's Recent Stock Surge - Kavout
(OGN) Risk Channels and Responsive Allocation - Stock Traders Daily
Sun Pharma to acquire Organon in US$11bn deal - FemTech World
OGN Stock Chart | ORGANON & CO (NYSE:OGN) - ChartMill
OGN Technical Analysis | Trend, Signals & Chart Patterns | ORGANON & CO (NYSE:OGN) - ChartMill
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Organon & Co. (OGN) - marketscreener.com
OGN CLASS ACTION NEWS: Organon & Co. Shareholders that Suffered Losses are Alerted of the Upcoming July 22 Securities Fraud Class Action Deadline - TMX Newsfile
OGN Stock Price, Quote & Chart | ORGANON & CO (NYSE:OGN) - ChartMill
Sun Pharma, Organon filed HSR May 21, waiting period expires June 22 - MLex
OGN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Organon (OGN) to be Acquired by Sun Pharma for $14.00 Cash per Share - Stock Titan
Sun Pharma bought the dip in its $11.7B Organon deal. Just not the right kind of dip - The Ken
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know - Yahoo Finance
Organon Co Stock (OGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.80%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):